The Avastin Dilemma: Two Personalities and Two Points of View on Cost Effectiveness
• By Michael McCaughan
Two of the key figures in the 2009 health reform debate, Zeke Emanuel and Billy Tauzin, each use Genentech's Avastin to demonstrate the importance of doing cost effectiveness right. But they look at the same drug from very different points of view. Their perspectives provide a good guide to what is at stake in the design of federal approach to comparative effectiveness research.
By Michael McCaughan
When Pharmaceutical Research & Manufacturers of America CEO Billy Tauzin talks about the dangers of government-run cost effectiveness systems, he...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
HHS and its agencies violated the law by swiftly implementing “sweeping and poorly thought-through directives that ordered the bulk removal of healthcare resources,” including FDA draft guidances on diversity action plans and sex differences in clinical trials, a federal court said.
The legislation expected to be signed by President Trump is a mixed bag for pharmaceutical manufacturers depending on their product mix and manufacturing situation.
Industry associations EFPIA, EUCOPE and EURORDIS have praised the European Commission’s newly launched life sciences strategy, which will see investment funnelled into improving the clinical trial ecosystem and supporting advanced therapy development.